Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiethylperazine amyloid-beta efflux study in early-to-mild Alzheimer's disease and healthy volunteers
2014-000870-20Phase 2Terminated
- Sponsor
- Immungenetics AG
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiethylperazine in Alzheimer's disease (AD) (2 arms), sponsored by Immungenetics AG. Primary endpoint: Change in plasma amyloid beta. Started Sep 2014; status: terminated.
02
Drugs
thiethylperazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-000870-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000870-20.